Share This Page
Drug Price Trends for GENOTROPIN MINIQUICK
✉ Email this page to a colleague
Average Pharmacy Cost for GENOTROPIN MINIQUICK
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GENOTROPIN MINIQUICK 0.2 MG | 00013-2649-02 | 29.07021 | EACH | 2024-12-18 |
| GENOTROPIN MINIQUICK 0.6 MG | 00013-2651-02 | 88.22163 | EACH | 2024-12-18 |
| GENOTROPIN MINIQUICK 0.4 MG | 00013-2650-02 | 58.68334 | EACH | 2024-12-18 |
| GENOTROPIN MINIQUICK 0.4 MG | 00013-2650-02 | 58.73086 | EACH | 2024-11-20 |
| GENOTROPIN MINIQUICK 0.6 MG | 00013-2651-02 | 88.12929 | EACH | 2024-11-20 |
| GENOTROPIN MINIQUICK 0.2 MG | 00013-2649-02 | 29.05939 | EACH | 2024-11-20 |
| GENOTROPIN MINIQUICK 0.6 MG | 00013-2651-02 | 88.12929 | EACH | 2024-10-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
GENOTROPIN MINIQUICK Market Analysis and Financial Projection
Market Analysis and Price Projections for GENOTROPIN MINIQUICK
Introduction to GENOTROPIN MINIQUICK
GENOTROPIN MINIQUICK is a recombinant human growth hormone (somatropin) produced by recombinant DNA technology in Escherichia coli cells. It is formulated as a powder and solvent for solution for injection, designed for subcutaneous administration. This medication is indicated for the treatment of various growth disturbances, including growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, and other conditions such as Prader-Willi syndrome and idiopathic short stature[1][5].
Market Size and Growth
The global human growth hormone (hGH) market, which includes GENOTROPIN MINIQUICK, is projected to experience significant growth. By 2025, the market is expected to reach $7.1 billion, growing at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period. This growth is driven by increasing prevalence of chronic diseases such as growth retardation, GHD in the elderly, and rising cases of pituitary dysfunction[3].
Key Indications and Patient Segments
GENOTROPIN MINIQUICK is used to treat a variety of conditions, including:
- Growth Hormone Deficiency (GHD): In children and adults where the pituitary gland does not produce sufficient growth hormone.
- Turner Syndrome: A genetic disorder affecting females, characterized by short stature.
- Chronic Renal Insufficiency: Growth failure associated with chronic kidney disease.
- Prader-Willi Syndrome: A genetic disorder leading to short stature and other developmental issues.
- Idiopathic Short Stature: Non-GHD short stature in children[1][5].
Pricing and Cost Analysis
The pricing of GENOTROPIN MINIQUICK varies based on the dosage and packaging. Here are some key price points:
- GENOTROPIN MINIQUICK 0.2 MG: $212.50 per unit
- GENOTROPIN MINIQUICK 0.4 MG: $425.06 per unit
- GENOTROPIN MINIQUICK 0.6 MG: $637.56 per unit
- GENOTROPIN MINIQUICK 1 MG: $1,062.64 per unit
- GENOTROPIN MINIQUICK 1.2 MG: $1,275.16 per unit
- GENOTROPIN MINIQUICK 2 MG: $2,125.22 per unit[2].
Cost Comparison with Other hGH Products
GENOTROPIN MINIQUICK's cost is compared to other recombinant human growth hormone products:
- Daily Cost: The daily cost of the maximum dose of GENOTROPIN is less than that of Humatrope and Nutropin but higher than Saizen.
- Annual Cost: The annual cost of GENOTROPIN is lower than Humatrope and Nutropin but higher than Saizen. For example, the annual cost for GENOTROPIN can be around $15,863, compared to $15,863 for Humatrope and $12,126 for Saizen[4].
Pharmacoeconomic Analysis
Pharmacoeconomic studies suggest that GENOTROPIN could offer cost savings compared to some other hGH products. According to the Common Drug Review, using a confidential price per milligram, GENOTROPIN could be associated with cost savings of up to $1,317,168 per year for public plans. This is due to its lower daily and annual costs compared to certain competitors[4].
Market Drivers and Challenges
Drivers
- Increasing Prevalence of Chronic Diseases: Growth retardation, GHD in the elderly, and pituitary dysfunction are becoming more prevalent, driving the demand for hGH treatments.
- Advancements in Technology: Improvements in recombinant DNA technology have made hGH production more efficient and cost-effective.
- Expanding Indications: The approval of hGH for additional conditions, such as Prader-Willi syndrome and idiopathic short stature, broadens the patient base[3].
Challenges
- High Treatment Costs: Despite some cost savings, hGH treatments remain expensive, which can be a barrier to access for many patients.
- Regulatory Hurdles: Strict regulatory requirements and patent laws can affect the market dynamics and pricing strategies of hGH products[5].
Future Outlook and Price Projections
Given the projected market growth and increasing demand, the prices of GENOTROPIN MINIQUICK and other hGH products are likely to remain stable or see moderate increases. Here are some key points for future outlook:
- Market Growth: The hGH market is expected to continue growing, driven by increasing demand and expanding indications.
- Price Stability: Prices may remain stable due to competitive market dynamics and pharmacoeconomic considerations.
- Innovation: Continued advancements in technology could lead to more efficient production methods, potentially reducing costs and making treatments more accessible[3].
Key Takeaways
- Market Growth: The global hGH market is projected to reach $7.1 billion by 2025.
- Pricing: GENOTROPIN MINIQUICK prices vary by dosage, with costs comparable to or lower than some competitors.
- Cost Savings: GENOTROPIN can offer cost savings compared to other hGH products.
- Drivers and Challenges: Increasing prevalence of chronic diseases and technological advancements drive the market, while high treatment costs and regulatory hurdles present challenges.
- Future Outlook: The market is expected to grow, with prices likely remaining stable or seeing moderate increases.
FAQs
What is GENOTROPIN MINIQUICK used for?
GENOTROPIN MINIQUICK is used for the treatment of growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and idiopathic short stature.
How is GENOTROPIN MINIQUICK administered?
GENOTROPIN MINIQUICK is administered via subcutaneous injection using a two-chamber cartridge with a powder and solvent.
What are the key drivers of the hGH market growth?
The key drivers include increasing prevalence of chronic diseases such as growth retardation and pituitary dysfunction, and advancements in recombinant DNA technology.
How does the cost of GENOTROPIN MINIQUICK compare to other hGH products?
The cost of GENOTROPIN MINIQUICK is generally lower than that of Humatrope and Nutropin but higher than Saizen.
What is the projected market size for the hGH market by 2025?
The global hGH market is expected to reach $7.1 billion by 2025, growing at a CAGR of 8.3%.
Sources
- Medicines.org.uk: Genotropin 1mg MiniQuick - Summary of Product Characteristics.
- Pfizer: Information for Connecticut Prescribers of Prescription Drugs - Pfizer.
- KBV Research: Human Growth Hormone Market Size to Reach USD 7.1 Bn by 2025.
- CDA-AMC: Pharmacoeconomic Review Report: somatropin (Genotropin).
- GlobalData: Net Present Value Model: Genotropin.
More… ↓
